<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03997968</url>
  </required_header>
  <id_info>
    <org_study_id>CYT-0851-01</org_study_id>
    <nct_id>NCT03997968</nct_id>
  </id_info>
  <brief_title>A Phase 1/2 Study of CYT-0851, an Oral RAD51 Inhibitor, in B-Cell Malignancies and Advanced Solid Tumors</brief_title>
  <official_title>A Multi-Center, Open Label Phase 1/2 Study of CYT-0851, an Oral RAD51 Inhibitor, in Patients With Relapsed/Refractory B-Cell Malignancies and Advanced Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cyteir Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cyteir Therapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This clinical trial is an interventional, active-treatment, open-label, multi-center, Phase&#xD;
      1/2 study. The study objectives are to assess the safety, tolerability and pharmacokinetics&#xD;
      (PK) of the oral RAD51 inhibitor CYT-0851 in patients with relapsed/refractory B-cell&#xD;
      malignancies and advanced solid tumors and to identify a recommended Phase 2 dose as a&#xD;
      monotherapy and in combination with chemotherapy for evaluation in these patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Overexpression of activation-induced cytidine deaminase (AID) or other cytidine deaminases&#xD;
      causes high rates of deoxyribonucleic acid (DNA) damage (mutations, double strand DNA breaks,&#xD;
      and chromosome rearrangements) in a high number of patients with B-cell malignancies, such as&#xD;
      NHL, MM, and CLL, and in a subset of patients with solid tumors, such as non-small cell lung&#xD;
      cancer (NSCLC), sarcoma, breast cancer, ovarian cancer, and squamous cell carcinoma of the&#xD;
      head and neck. Cancer cells that overexpress AID and other cytidine deaminases rely on RAD51,&#xD;
      a protein involved in homologous recombination, to repair the DNA damage caused by cytidine&#xD;
      deaminases. Inhibition of RAD51 with CYT-0851 in preclinical models induces cell death, tumor&#xD;
      growth delay or tumor regression.&#xD;
&#xD;
      The Phase 1 part of the study will follow an accelerated titration design, which includes&#xD;
      enrollment of single patient cohorts until certain criteria are met, followed by a standard&#xD;
      3+3 design. This design will allow for identification of a recommended phase 2 dose (RP2D)&#xD;
      level while dosing the least number of patients as possible at potentially sub-therapeutic&#xD;
      doses. Upon identification of the RP2D in the monotherapy, the study will open to three&#xD;
      combination treatment arms to identify the RP2D in combination with rituximab and&#xD;
      bendamustine in Non-Hodgkin Lymphoma and capecitabine or gemcitabine for solid tumors. In the&#xD;
      Phase 2 part of the study, preliminary efficacy will be evaluated in 8 expansion cohorts&#xD;
      (total n = 92-220), using a Simon two-stage design. The RP2D will be selected based on the&#xD;
      MTD, the safety profile, PK, and available pharmacodynamics data generated from all subjects&#xD;
      in Phase 1.&#xD;
&#xD;
      In both Phase 1 and Phase 2, patients will be treated in continuous 21-day or 28-day cycles&#xD;
      and all patients will be assessed for response every 2 cycles. Treatment will be terminated&#xD;
      if the patient progresses, cannot tolerate treatment, or withdraws consent from active&#xD;
      therapy. Patients will undergo a safety evaluation approximately 1 month (28-35 days) after&#xD;
      the last dose. Patients will be followed for response until progression is documented.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 9, 2019</start_date>
  <completion_date type="Anticipated">October 2022</completion_date>
  <primary_completion_date type="Anticipated">September 2021</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Dose limiting Toxicity</measure>
    <time_frame>Phase 1: 12 months;</time_frame>
    <description>Identify nature and frequency of dose limiting toxicities</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall Response Rate</measure>
    <time_frame>24 Months</time_frame>
    <description>Percent of Patients responding to treatment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>24 months</time_frame>
    <description>Evaluate the safety of CYT-0851&#xD;
Establish the PK of CYT-0851 Evaluate the type and frequency of adverse events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood CYT-0851 concentrations</measure>
    <time_frame>Phase 1: 12 months</time_frame>
    <description>Measure CYT-0851 concentrations over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response</measure>
    <time_frame>24 months</time_frame>
    <description>For responders, time from response to progression</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>24 months</time_frame>
    <description>Time from treatment start to death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>24 months</time_frame>
    <description>Time from treatment start to progression or death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Laboratory and ECG abnormalities</measure>
    <time_frame>24 months</time_frame>
    <description>Percentage of grade of laboratory and ECG abnormalities</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">320</enrollment>
  <condition>Malignancy</condition>
  <condition>Non-hodgkin Lymphoma</condition>
  <condition>Multiple Myeloma</condition>
  <condition>Breast Cancer</condition>
  <condition>Ovarian Cancer</condition>
  <condition>Soft Tissue Sarcoma</condition>
  <condition>Head and Neck Cancer</condition>
  <condition>DLBCL</condition>
  <condition>Mantle Cell Lymphoma</condition>
  <condition>Follicular Lymphoma</condition>
  <condition>Pancreatic Cancer</condition>
  <condition>CLL</condition>
  <condition>Small Cell Lung Cancer</condition>
  <condition>Squamous Cell Carcinoma of Head and Neck</condition>
  <condition>Triple Negative Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Experimental: Active treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This is an open label study. All patients will receive single agent CYT-0851 administered orally or CYT-0851 in combination with chemotherapy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CYT-0851</intervention_name>
    <description>Montherapy patients will receive CYT-0851 as a single agent</description>
    <arm_group_label>Experimental: Active treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CYT-0851</intervention_name>
    <description>Combination arm patients will receive CYT-0851 in combination with chemotherapy</description>
    <arm_group_label>Experimental: Active treatment</arm_group_label>
    <other_name>Gemcitabine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CYT-0851</intervention_name>
    <description>Combination arm patients will receive CYT-0851 in combination with anti-CD20 antibody and chemotherapy</description>
    <arm_group_label>Experimental: Active treatment</arm_group_label>
    <other_name>Rituximab</other_name>
    <other_name>Bendamustine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Phase 1 Inclusion Criteria&#xD;
&#xD;
          1. Male or female â‰¥18 years of age at time of informed consent.&#xD;
&#xD;
               1. Female subjects of childbearing potential must be non-lactating, not pregnant as&#xD;
                  confirmed by a negative serum pregnancy test at most 30 days before enrollment&#xD;
                  and within 72 hours before the first administration of CYT-0851&#xD;
&#xD;
               2. Female subjects of childbearing potential must not donate ova during the study&#xD;
                  and for at least 90 days after the last dose of study drug and must agree to&#xD;
                  continue using an effective method of contraception during the screening period&#xD;
                  to first study drug administration until 90 days after the last dose of study&#xD;
                  drug&#xD;
&#xD;
               3. Male subjects who have not had a vasectomy must agree to use an effective method&#xD;
                  of contraception during the study and until 90 days after the last dose of the&#xD;
                  study drug, and to not donate sperm during the study and for at least 90 days&#xD;
                  after the last dose of study drug&#xD;
&#xD;
          2. ECOG Performance Status of 0-1&#xD;
&#xD;
          3. Measurable disease defined by disease-specific response criteria&#xD;
&#xD;
          4. Histologically-proven B cell malignancies, meeting the following criteria:&#xD;
&#xD;
               1. Relapsed, refractory B-cell non-Hodgkin lymphoma requiring therapy, after at&#xD;
                  least two prior therapies, and if transplanted, then at least 3-month post&#xD;
                  autologous stem cell transplant and if CART-treated, then evidence of progression&#xD;
                  no sooner than 3 months post CART treatment, or&#xD;
&#xD;
               2. Relapsed, refractory chronic lymphocytic leukemia requiring therapy after at&#xD;
                  least two prior therapies, including BTK and BCL-2 inhibitor therapy (unless&#xD;
                  ineligible for such therapy), or&#xD;
&#xD;
               3. For multiple myeloma, relapsed or progressive on or after treatment with at least&#xD;
                  three prior therapies that included a proteasome inhibitor, an imide,&#xD;
                  daratumumab, and if transplant eligible, a bone marrow transplant (unless unfit&#xD;
                  for transplant), or&#xD;
&#xD;
          5. Histologically-proven solid tumor meeting the following criteria:&#xD;
&#xD;
               1. Patients must have failed, refused, or not be eligible for further standard&#xD;
                  therapies (including chemotherapy, hormonal therapies, Her-2 directed therapies,&#xD;
                  as appropriate) expected to provide clinical benefit, and meeting the following&#xD;
                  criteria&#xD;
&#xD;
               2. Metastatic breast cancer (including ER/PR positive or negative, Her-2 positive&#xD;
                  and negative, triple negative), treated with at least 1 prior therapy for&#xD;
                  metastatic disease, or&#xD;
&#xD;
               3. Recurrent squamous cell carcinoma of the head and neck (HNSCC) (dose escalation)&#xD;
                  or human papilloma virus positive (HPV+) HNSCC (dose-escalation and backfill),&#xD;
                  treated with at least 1 prior therapy, or&#xD;
&#xD;
               4. Ovarian cancer, progressive after treatment with at least prior platinum-based&#xD;
                  chemotherapy, and therapy with a PARP inhibitor or&#xD;
&#xD;
               5. Soft tissue sarcoma, treated with at least one line of prior systemic therapy, or&#xD;
&#xD;
               6. Recurrent metastatic or locally advanced pancreatic cancer after first line&#xD;
                  chemotherapy (backfill patients only) or&#xD;
&#xD;
               7. Histologically-proven advanced small-cell lung cancer (SCLC) (backfill patients&#xD;
                  only).&#xD;
&#xD;
                    1. Patients with mixed histology are not allowed&#xD;
&#xD;
                    2. Prior treatment with platinum containing chemotherapy regimen with no&#xD;
                       evidence of progression within 90 days of last dose of platinum agent and&#xD;
                       anti-PD-(L)1 unless contraindicated&#xD;
&#xD;
                    3. At least 1 prior line of chemotherapy, but no more than 3 prior lines of&#xD;
                       therapy&#xD;
&#xD;
          6. Understands the procedures and requirements of the study and provides written informed&#xD;
             consent and authorization for protected health information disclosure&#xD;
&#xD;
          7. Willing and able to comply with the requirements of the study protocol&#xD;
&#xD;
          8. Site of disease amenable to a biopsy and willing to undergo biopsy required for&#xD;
             backfill, or for dose-escalation if considered unsafe (approval to participate in the&#xD;
             study required by the Medical Monitor) provide an archival sample â‰¤ 12 months old&#xD;
&#xD;
        Key Phase 2 Inclusion Criteria&#xD;
&#xD;
          1. Male or female â‰¥18 years of age at time of informed consent.&#xD;
&#xD;
               1. Female subjects of childbearing potential must be non-lactating, not pregnant as&#xD;
                  confirmed by a negative serum pregnancy test at most 30 days before enrollment&#xD;
                  and within 72 hours before the first administration of CYT-0851&#xD;
&#xD;
               2. Female subjects of childbearing potential must not donate ova during the study&#xD;
                  and for at least 90 days after the last dose of study drug and must agree to&#xD;
                  continue using, an effective method of contraception during the screening period&#xD;
                  to first study drug administration until 90 days after the last dose of study&#xD;
                  drug&#xD;
&#xD;
               3. Male subjects who have not had a vasectomy must agree to use an effective method&#xD;
                  of contraception during the study and until 90 days after the last dose of the&#xD;
                  study drug, and to not donate sperm during the study and for at least 90 days&#xD;
                  after the last dose of study drug&#xD;
&#xD;
          2. ECOG Performance Status of 0-1&#xD;
&#xD;
          3. Measurable disease defined by disease-specific response criteria&#xD;
&#xD;
          4. Site of disease amenable to a biopsy and willing to undergo a biopsy for the&#xD;
             determination of biomarker status, or, if considered unsafe (approval to participate&#xD;
             in the study required by the Medical Monitor), archival sample â‰¤ 12 months old for&#xD;
             determination of biomarker status.&#xD;
&#xD;
          5. Biomarker positive on recent biopsy or bone marrow sample if required for the specific&#xD;
             cohort.&#xD;
&#xD;
          6. Histologically-proven B cell malignancies, meeting the following criteria:&#xD;
&#xD;
               1. DLBCL Cohort&#xD;
&#xD;
                    1. Histologically-documented DLBCL or double hit lymphoma (B-cell lymphoma,&#xD;
                       unclassifiable, with features intermediate between diffuse large B-cell&#xD;
                       lymphoma and Burkitt lymphoma with BCL2 and MYC translocations (WHO&#xD;
                       Classification)&#xD;
&#xD;
                    2. Progressing on or after treatment with at least two prior lines of therapy,&#xD;
                       including R-CHOP or equivalent first line therapy&#xD;
&#xD;
                    3. If transplanted, then at least 3-month post autologous stem cell transplant&#xD;
&#xD;
                    4. If CART-treated, then evidence of progression no sooner than 3 months post&#xD;
                       CART treatment&#xD;
&#xD;
               2. MCL Cohort&#xD;
&#xD;
                    1. Histologically-documented MCL&#xD;
&#xD;
                    2. Any stage at diagnosis&#xD;
&#xD;
                    3. Progressing on or after treatment with at least 2 prior lines of therapy,&#xD;
                       including a Bruton tyrosine kinase (BTK) inhibitor, after a 14-day washout&#xD;
                       period&#xD;
&#xD;
               3. Multiple Myeloma Cohort 1) Relapsed or progressing after treatment with at least&#xD;
                  3 prior therapies that include a proteasome inhibitor, an Immunomodulatory imide&#xD;
                  drug (IMiD), daratumumab, and, if transplant eligible, a bone marrow transplant&#xD;
                  (unless unfit for transplant)&#xD;
&#xD;
          7. Or Histologically-proven solid tumors meeting the following criterial&#xD;
&#xD;
               1. Patients must have failed, refused, or not be eligible for further standard&#xD;
                  therapies (including chemotherapy, hormonal therapies, Her-2 directed therapies,&#xD;
                  as appropriate) expected to provide clinical benefit, and meeting the following&#xD;
                  criteria&#xD;
&#xD;
               2. Triple Negative Breast Cancer Cohort&#xD;
&#xD;
                    1. Histologically-documented triple negative breast cancer, ER/PR negative&#xD;
                       (defined as &lt;10% of cells expressing hormonal receptors via&#xD;
                       immunohistochemistry (IHC) analysis), and HER2-negative, defined as either&#xD;
                       of the following by local laboratory assessment:&#xD;
&#xD;
                         -  In situ hybridization (ISH) non-amplified (ratio of HER2 to CEP17 &lt; 2.0&#xD;
                            or single probe average HER2 gene copy number &lt; 4 signals/cell), or&#xD;
&#xD;
                         -  IHC 0 or IHC 1+&#xD;
&#xD;
                    2. At least 1 prior line of chemotherapy, but no more than 5 prior lines of&#xD;
                       chemotherapy&#xD;
&#xD;
               3. Ovarian Cancer Cohort&#xD;
&#xD;
                    1. Histologically-proven metastatic epithelial ovarian cancer&#xD;
&#xD;
                    2. Prior treatment with a platinum containing chemotherapy regimen&#xD;
&#xD;
                    3. Prior treatment with PARP inhibitor, and, unless in adjuvant setting,&#xD;
                       responsive to PARP inhibitor, with progression on or following PARP&#xD;
                       inhibitor treatment&#xD;
&#xD;
                    4. At least 1 prior line of therapy, but no more than 5 prior lines of&#xD;
                       chemotherapy&#xD;
&#xD;
               4. Pancreatic Cancer Cohort 1) Histologically-proven metastatic or locally advanced&#xD;
                  pancreatic cancer 2) At least 1 prior line of chemotherapy but no more than 4&#xD;
                  prior lines of systemic therapy&#xD;
&#xD;
               5. Soft Tissue Sarcoma Cohort&#xD;
&#xD;
                    1. Histologically-proven advanced soft-tissue sarcoma excluding all types of&#xD;
                       adipocytic sarcoma and GIST&#xD;
&#xD;
                    2. At least 1 prior line of systemic therapy (unless no standard of care&#xD;
                       exists), but no more than 5 prior lines of systemic therapy&#xD;
&#xD;
          8. Follicular Lymphoma Cohort&#xD;
&#xD;
               1. Histologically-documented follicular lymphoma&#xD;
&#xD;
               2. Relapsed, refractory follicular lymphoma requiring therapy, after at least two&#xD;
                  prior therapies, and if CART-treated, then evidence of progression no sooner than&#xD;
                  3 months post CART treatment&#xD;
&#xD;
          9. Understands the procedures and requirements of the study and provides written informed&#xD;
             consent and authorization for protected health information disclosure&#xD;
&#xD;
         10. Willing and able to comply with the requirements of the study protocol&#xD;
&#xD;
        Key Exclusion Criteria&#xD;
&#xD;
          1. Medical Conditions&#xD;
&#xD;
               1. Known history of HIV&#xD;
&#xD;
               2. Known history of viral hepatitis B unless HBV viral load is below the limit of&#xD;
                  quantification and off viral suppressive therapy&#xD;
&#xD;
               3. Know history of hepatitis C unless antiviral treatment with curative intent&#xD;
                  completed and HCV viral load is below the limit of quantification.&#xD;
&#xD;
               4. Myocardial infarction or stroke within 6 months&#xD;
&#xD;
               5. Uncontrolled hypertension (systolic blood pressure (SBP) &gt; 160 or diastolic blood&#xD;
                  pressure (DBP) &gt;100 on maximal medical therapy)&#xD;
&#xD;
               6. History of interstitial pulmonary disease&#xD;
&#xD;
               7. Unresolved pneumonitis&#xD;
&#xD;
               8. Grade â‰¥ 3 neuropathy&#xD;
&#xD;
               9. Known active central nervous system (CNS) metastases. Subjects with previously&#xD;
                  treated CNS metastases may participate as long as clinically and radiologically&#xD;
                  stable for at least 4 weeks after treatment, have no evidence of new or enlarging&#xD;
                  lesions and are off steroids and asymptomatic for 28 days prior to dosing with&#xD;
                  study medication&#xD;
&#xD;
              10. Known history of meningeal involvement or meningeal carcinomatosis&#xD;
&#xD;
              11. Spinal cord compression not definitively treated with surgery and/or radiation,&#xD;
                  or previously diagnosed and treated spinal cord compression without evidence that&#xD;
                  disease has been clinically stable for &gt; 2 weeks prior to screening visit&#xD;
&#xD;
              12. Presence of clinically significant cataracts&#xD;
&#xD;
              13. Second malignancy, except treated basal cell or localized squamous skin&#xD;
                  carcinomas, localized prostate cancer, or other malignancy that is in remission&#xD;
                  or stable and for which patients have not been on active anti-cancer therapy for&#xD;
                  2 years&#xD;
&#xD;
              14. Pregnant or lactating. If Î²-HCG is elevated, eligible if ultrasound confirms&#xD;
                  absence of a pregnancy.&#xD;
&#xD;
              15. Dementia or significantly altered metal status&#xD;
&#xD;
          2. Prior/Concomitant Therapy&#xD;
&#xD;
             a. Prior allogeneic stem cell transplant b. On systemic antibiotic, antifungal or&#xD;
             anti-viral therapy c. White blood cell (WBC) growth factors administered within 14&#xD;
             days of screening visit d. Cancer therapy within 14 days prior to treatment with study&#xD;
             drug e. On narrow therapeutic index medications (see Section 7.6.1 for list of drugs)&#xD;
             that are sensitive substrates of CYP3A, P-gp or BCRP (or caution is warranted with&#xD;
             approval by the Sponsor).&#xD;
&#xD;
             f. On any drug known to prolong QTc interval (eg, certain antiarrhythmic,&#xD;
             antimicrobials) that cannot be discontinued or interrupted 72 hours before the Day 1&#xD;
             dose through Day 2, and 72 hours before the Day 15 dose until Day 16 (BID dosing) or&#xD;
             the Day 22 dose until Day 23 (QD dosing), in Cycle 1 (see Section 7.6.1 for a list of&#xD;
             drugs).&#xD;
&#xD;
             g. On systemic corticosteroid treatment for non-tumor indication at a daily dose&#xD;
             equivalent to &gt;10mg of Prednisone&#xD;
&#xD;
          3. Prior/Concurrent Clinical Study Experience&#xD;
&#xD;
             a. Participation in another clinical trial (unless in the observation phase, or an&#xD;
             observational study), or exposure to any investigational agent within 14 days prior to&#xD;
             treatment with study drug&#xD;
&#xD;
          4. Laboratory assessments&#xD;
&#xD;
               1. Complete blood count (CBC):&#xD;
&#xD;
                  Monotherapy and Chemotherapy Combinations 1 and 2:&#xD;
&#xD;
                    1. ANC &lt; 1.0 Ã— 10^9/L&#xD;
&#xD;
                    2. PLT &lt; 75 Ã— 10^9/L&#xD;
&#xD;
                    3. Hgb &lt; 9.0 g/dL&#xD;
&#xD;
                       Chemotherapy Combination Group 3:&#xD;
&#xD;
                  1) ANC &lt; 1.5 Ã— 10^9/L 2) PLT &lt; 100 Ã— 10^9/L 3) Hgb &lt; 9.0 g/dL&#xD;
&#xD;
                  Monotherapy and Chemotherapy Combination Groups 1 and 2:&#xD;
&#xD;
               2. Calculated Creatinine clearance (Cockcroft-Gault) &lt; 40 mL/min&#xD;
&#xD;
        Chemotherapy Combination Group 3:&#xD;
&#xD;
        b. Calculated Creatinine clearance (Cockcroft-Gault) &lt; 50 mL/min c. Hepatic function&#xD;
&#xD;
          1. AST &gt; 2.0 Ã— ULN&#xD;
&#xD;
          2. ALT &gt; 2.0 Ã— ULN d. Total bilirubin &gt; 1.5 x ULN e. Albumin &lt; 2.8 g/dL 5. ECG Exclusion&#xD;
             a. Screening QTc interval &gt; 450 milliseconds for males and QTc &gt; 470 ms for females&#xD;
             (corrected by Fridericia) 6. Other Exclusions&#xD;
&#xD;
               1. Unwilling or unable to make all planned study visits&#xD;
&#xD;
               2. Unwilling or unable to provide a recent biopsy or bone marrow sample prior to&#xD;
                  enrollment and during study; Note: certain exceptions may be permitted allowing&#xD;
                  archival specimens prior to treatment or for subjects where a specimen is not&#xD;
                  required for biomarker positive testing (see Sections 6.1.9.1 and 6.2.8)&#xD;
&#xD;
               3. Significant medical diseases or conditions, as assessed by the Investigators and&#xD;
                  Cyteir that would substantially increase the risk-benefit ratio of participating&#xD;
                  in the study. This includes but is not limited to acute myocardial infarction,&#xD;
                  arterial thrombosis, significant gastrointestinal bleed, or unstable angina&#xD;
                  within the last 6 months uncontrolled diabetes mellitus, current active&#xD;
                  infections, severely immunocompromised state, and congestive heart failure New&#xD;
                  York Heart Association (NYHA) Class III-IV, left ventricular ejection fraction&#xD;
                  (LVEF) &lt; 40% d: Chemotherapy Combination Group 3 only: known history of&#xD;
                  dhydropyrimidine dehydrogenase deficiency&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Judson Englert, MD</last_name>
    <role>Study Director</role>
    <affiliation>Cyteir Therapeutics</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Judson Englert, MD</last_name>
    <phone>857-285-4140</phone>
    <email>clinicaltrials@cyteir.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Susan Doleman</last_name>
    <phone>857-285-4140</phone>
    <email>clinicaloperations@cyteir.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85259</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Trials Referral Office</last_name>
      <phone>855-776-0015</phone>
    </contact>
    <investigator>
      <last_name>Mahesh Seetharam, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of California San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94158</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lauren Wilch</last_name>
      <phone>415-353-3642</phone>
      <email>Lauren.Wilch@ucsf.edu</email>
    </contact>
    <investigator>
      <last_name>Pamela Munster, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Stanford Comprehensive Cancer Center</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mariel Rojas</last_name>
      <phone>650-723-0530</phone>
      <email>mlrojas@stanford.edu</email>
    </contact>
    <investigator>
      <last_name>Ranjana Advani, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sarah Cannon Research Institute at HealthONE</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80218</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Susan Hall</last_name>
      <phone>720-754-2610</phone>
      <email>Susan.Hall3@sarahcannon.com</email>
    </contact>
    <investigator>
      <last_name>Shiraj Sen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32224</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Trials Referral Office</last_name>
      <phone>855-776-0015</phone>
    </contact>
    <investigator>
      <last_name>Han Win Tun, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Florida Cancer Specialists and Research Institute</name>
      <address>
        <city>Sarasota</city>
        <state>Florida</state>
        <zip>34232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karolyn Simpson, RN</last_name>
      <phone>941-377-9993</phone>
      <email>KaSimpson@flcancer.com</email>
    </contact>
    <investigator>
      <last_name>Manesh R Patel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dejan Juric, MD</last_name>
      <phone>617-724-4000</phone>
      <email>djuric@partners.org</email>
    </contact>
    <investigator>
      <last_name>Dejan Juric, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dana Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>877-338-7425</phone>
    </contact>
    <investigator>
      <last_name>Geoffrey I. Shapiro, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Michigan</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Monica Burness, MD</last_name>
      <phone>734-232-0759</phone>
      <email>mburness@med.umich.edu</email>
    </contact>
    <investigator>
      <last_name>Monica Burness, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Trials Referral Office</last_name>
      <phone>855-776-0015</phone>
    </contact>
    <investigator>
      <last_name>Grzegorz S Nowakowski, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>John Theurer Cancer Center at HUMC</name>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <zip>07601</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chelsea McCabe</last_name>
      <phone>551-996-4725</phone>
      <email>chelsea.mccabe@hackensackmeridian.org</email>
    </contact>
    <investigator>
      <last_name>Martin Gutierrez, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>NYU Langone Health</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nina Beri, MD</last_name>
      <phone>212-731-5770</phone>
      <email>Nina.Beri@nyulangone.org</email>
    </contact>
    <investigator>
      <last_name>Nina Beri, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Oklahoma University-Stephenson Cancer Center</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>405-271-8778</phone>
      <email>PhaseI-Referrals@ouhsc.edu</email>
    </contact>
    <investigator>
      <last_name>Kathleen Moore, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Thomas Jefferson University, Sidney Kimmel Cancer Center</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dennis Stone</last_name>
      <phone>215-955-6407</phone>
      <email>Dennis.Stone@Jefferson.edu</email>
    </contact>
    <investigator>
      <last_name>Neil Palmisiano, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sarah Cannon Research Institute at Tennessee Oncology</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Davinia McComb, RN, OCN</last_name>
      <phone>615-815-9963</phone>
    </contact>
    <investigator>
      <last_name>Johanna C Bendell, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The University of Texas MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sarah Travasos</last_name>
      <phone>713-563-4431</phone>
      <email>sktravasos@mdanderson.org</email>
    </contact>
    <investigator>
      <last_name>Timothy A Yap, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Washington Seattle Cancer Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Harini Ramachandran</last_name>
      <phone>206-606-6448</phone>
      <email>harinir@seattlecca.org</email>
    </contact>
    <investigator>
      <last_name>Ryan Lynch, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medical College of Wisconsin</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Jacklin</last_name>
      <phone>414-804-8839</phone>
      <email>mjacklin@mcw.com</email>
    </contact>
    <investigator>
      <last_name>Mehdi Hamadani, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Lamont KR, Hasham MG, Donghia NM, Branca J, Chavaree M, Chase B, Breggia A, Hedlund J, Emery I, Cavallo F, Jasin M, RÃ¼ter J, Mills KD. Attenuating homologous recombination stimulates an AID-induced antileukemic effect. J Exp Med. 2013 May 6;210(5):1021-33.</citation>
    <PMID>23589568</PMID>
  </results_reference>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>June 24, 2019</study_first_submitted>
  <study_first_submitted_qc>June 24, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 25, 2019</study_first_posted>
  <last_update_submitted>August 6, 2021</last_update_submitted>
  <last_update_submitted_qc>August 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Oral RAD51-inhibitor; refractory; B-cell; solid tumor</keyword>
  <keyword>DNA Damage Repair inhibitor</keyword>
  <keyword>cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Sarcoma</mesh_term>
    <mesh_term>Lymphoma, Mantle-Cell</mesh_term>
    <mesh_term>Small Cell Lung Carcinoma</mesh_term>
    <mesh_term>Triple Negative Breast Neoplasms</mesh_term>
    <mesh_term>Squamous Cell Carcinoma of Head and Neck</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Bendamustine Hydrochloride</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

